T2	Participants 108 136	analysis of the VACT studies
T3	Participants 175 338	1578 patients with osteoarthritis randomized to take acetaminophen 4000 mg (n=269), celecoxib 200 mg (n=523), rofecoxib 12.5 mg (n=259), or rofecoxib 25 mg (n=527)
T1	Participants 12 63	rofecoxib, celecoxib, and acetaminophen in patients
#1	AnnotatorNotes T1	Efficacy in patients
T4	Participants 149 174	To compare efficacy among
#2	AnnotatorNotes T4	objective
#3	AnnotatorNotes T3	no of patients participate with this
T5	Participants 510 664	Days 1 to 6 and 6 weeks with Patient Global Assessment of Response to Therapy (PGART) and Western Ontario and McMaster Universities (WOMAC) Osteoarthritis
#4	AnnotatorNotes T5	patient evaluate day and therapy
